Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity
- PMID: 3387441
- PMCID: PMC280534
- DOI: 10.1073/pnas.85.13.4852
Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity
Abstract
Chimeric antibodies were constructed in which the murine variable region of anti-colorectal cancer monoclonal antibody CO17-1A was joined with human gamma 1, gamma 2, gamma 3, and gamma 4 constant regions. Human-mouse chimeric proteins were compared with the parental murine IgG2a antibody CO17-1A for their ability to participate in tumor-cell destruction by human and murine effector cells in antibody-dependent cell-mediated cytotoxicity (ADCC) assays. All of the chimeric antibodies showed different degrees of ADCC with human lymphocytes, monocytes, and granulocytes and with murine macrophages. Monocytes and macrophages were able to utilize the chimeric IgG1 and, to a lesser degree, IgG4 and IgG3 antibodies to lyse tumor-cell targets in ADCC assays. The chimeric IgG1 and IgG4 antibodies were nearly as effective as the parental CO17-1A antibody in inhibiting tumor growth in nude mice. These data indicate that chimeric IgG1 antibody is superior in its antitumor activity.
Similar articles
-
Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies.Cancer Res. 1990 Feb 1;50(3 Suppl):993s-999s. Cancer Res. 1990. PMID: 2297753
-
Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.Hum Antibodies Hybridomas. 1990;1(2):66-76. Hum Antibodies Hybridomas. 1990. PMID: 2103354
-
Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen.J Immunol. 1987 Jun 15;138(12):4534-8. J Immunol. 1987. PMID: 3584980
-
Targeted cellular immunotherapy with bifunctional antibodies.Cancer Cells. 1991 May;3(5):163-72. Cancer Cells. 1991. PMID: 1832553 Review.
-
Immunotherapy of colon cancer using chimeric mAb 31.1.Crit Rev Immunol. 1998;18(1-2):133-8. doi: 10.1615/critrevimmunol.v18.i1-2.140. Crit Rev Immunol. 1998. PMID: 9419455 Review.
Cited by
-
Biological characterization of a chimeric mouse-human IgM antibody directed against the 17-1A antigen.Cancer Immunol Immunother. 1989;30(1):43-50. doi: 10.1007/BF01665029. Cancer Immunol Immunother. 1989. PMID: 2598174 Free PMC article.
-
Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer.Jpn J Cancer Res. 2000 Aug;91(8):817-24. doi: 10.1111/j.1349-7006.2000.tb01019.x. Jpn J Cancer Res. 2000. PMID: 10965023 Free PMC article.
-
Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.Infect Immun. 2007 Mar;75(3):1424-35. doi: 10.1128/IAI.01161-06. Epub 2007 Jan 12. Infect Immun. 2007. PMID: 17220317 Free PMC article.
-
Assessment of Functional Characterization and Comparability of Biotherapeutics: a Review.AAPS J. 2021 Dec 20;24(1):15. doi: 10.1208/s12248-021-00671-0. AAPS J. 2021. PMID: 34931298 Review.
-
Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization.Proc Natl Acad Sci U S A. 2023 Apr 11;120(15):e2217590120. doi: 10.1073/pnas.2217590120. Epub 2023 Apr 3. Proc Natl Acad Sci U S A. 2023. PMID: 37011197 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources